Simeprevir: Phase III data

The open-label, Spanish Phase III PLUTO trial in 40 treatment-naive or -experienced patients with chronic HCV genotype 4 infection showed that once-daily 150 mg Olysio plus 400 mg Sovaldi sofosbuvir for 12 weeks met the primary endpoint of a greater proportion of patients achieving an SVR 12 weeks after the end of treatment vs. a historical control cohort of patients treated with Olysio plus peginterferon alfa-2a and ribavirin (100% vs. 61%). Data were presented at the European Association for the Study of the Liver meeting in Barcelona. ...